Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: A frequently sampled intravenous glucose tolerance test and minimal model analysis

Archives of General Psychiatry

Volumn 62, Issue 1, 2005, Pages 19-28

  Henderson, David C ^a,d,e   Cagliero, Enrico ^a,d   Copeland, Paul M ^a,d   Borba, Christina P ^a   Evins, Eden ^a,d   Hayden, Doug ^a   Weber, Mary T ^b   Anderson, Ellen J ^a   Allison, David B ^c   Daley, Tara B ^a   Schoenfeld, David ^a,d   Goff, Donald C ^d  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF TEXAS AT ARLINGTON   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e Freedom Trail Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; GLUCOSE; GROWTH HORMONE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROCORTISONE; INSULIN; LEPTIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OLANZAPINE; RISPERIDONE; TRIACYLGLYCEROL;

ADULT; ANTHROPOMETRY; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DEMOGRAPHY; DRUG EFFECT; FEMALE; FOOD INTAKE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GROWTH HORMONE BLOOD LEVEL; HUMAN; HYDROCORTISONE BLOOD LEVEL; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; INTRAVENOUS GLUCOSE TOLERANCE TEST; MALE; MENTAL HEALTH CENTER; OBESITY; PHYSICAL ACTIVITY; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL; URBAN POPULATION;

ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BLOOD GLUCOSE; BODY MASS INDEX; BODY WEIGHT; CLOZAPINE; DIABETES MELLITUS, TYPE 2; FEMALE; GLUCOSE TOLERANCE TEST; HUMANS; INSULIN RESISTANCE; MALE; METABOLIC SYNDROME X; OBESITY; RISPERIDONE; SCHIZOPHRENIA;

EID: 19944429395     PISSN: 0003990X     EISSN: None     Source Type: Journal    
DOI: 10.1001/archpsyc.62.1.19     Document Type: Article

References (64)

1. Harris E, Barraclough B. Excess mortality of mental disorder. Br J Psychiatry. 1998;173:11-53.
2. Newman SC, Bland RC. Mortality in a cohort of patients with schizophrenia: a record linkage study. Can J Psychiatry. 1991;36:239-245.
3. Henderson DC. Atypical antipsychotic-induced diabetes mellitus: how strong is the evidence? CNS Drugs. 2002;16:77-89.
4. Allison DB, Casey DE. Antipsychotic-induced weight gain: a review of the literature. J Clin Psychiatry. 2001;62(suppl 7):22-31.
5. Mir S, Taylor D. Atypical antipsychotics and hyperglycaemia. Int Clin Psychopharmacol. 2001;16:63-73.
6. Melkersson KI, Hulting AL, Brismar KE. Different influences of classical antipsychotics and clozapine on glucose-insulin homeostasis in patients with schizophrenia or related psychoses. J Clin Psychiatry. 1999;60:783-791.
7. Melkersson KI, Hulting AL, Brismar KE. Elevated levels of insulin, leptin, and blood lipids in olanzapine-treated patients with schizophrenia or related psychoses. J Clin Psychiatry. 2000;61:742-749.
8. Newcomer JW, Haupt DW, Fucetola R, Melson AK, Schweiger JA, Cooper BP, Selke G. Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia. Arch Gen Psychiatry. 2002;59:337-345.
9. Henderson DC, Cagliero E, Gray C, Nasrallah RA, Hayden DL, Schoenfeld DA, Goff DC. Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: a five-year naturalistic study. Am J Psychiatry. 2000;157:975-981.
10. Caro JJ, Ward A, Levinton C, Robinson K. The risk of diabetes during olanzapine use compared with risperidone use: a retrospective database analysis. J Clin Psychiatry. 2002;63:1135-1139.
11. Sernyak MJ, Leslie DL, Alarcon RD, Losonczy MF, Rosenheck R. Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. Am J Psychiatry. 2002;159:561-566.
12. Koro CE, Fedder DO, L'Italien GJ, Weiss SS, Magder LS, Kreyenbuhl J, Revicki DA, Buchanan RW. Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study. BMJ. 2002;325:243.
13. Lund BC, Perry PJ, Brooks JM, Arndt S. Clozapine use in patients with schizophrenia and the risk of diabetes, hyperlipidemia, and hypertension: a claims-based approach. Arch Gen Psychiatry. 2001;58:1172-1176.
14. Gianfrancesco FD, Grogg AL, Mahmoud RA, Wang RH, Nasrallah HA. Differential effects of risperidone, olanzapine, clozapine, and conventional antipsychotics on type 2 diabetes: findings from a large health plan database. J Clin Psychiatry. 2002;63:920-930.
15. Kornegay CJ, Vasilakis-Scaramozza C, Jick H. Incident diabetes associated with antipsychotic use in the United Kingdom general practice research database. J Clin Psychiatry. 2002;63:758-762.
16. Wang PS, Glynn RJ, Ganz DA, Schneeweiss S, Levin R, Avorn J. Clozapine use and risk of diabetes mellitus. J Clin Psychopharmacol. 2002;22:236-243.
17. Buse JB, Cavazzoni P, Hornbuckle K, Hutchins D, Breier A, Jovanovic L. A retrospective cohort study of diabetes mellitus and antipsychotic treatment in the United States. J Clin Epidemiol. 2003;56:164-170.
18. Koller E, Schneider B, Bennett K, Dubitsky G. Clozapine associated diabetes. Am J Med. 2001;111:716-723.
19. Koller EA, Doraiswamy PM. Olanzapine-associated diabetes mellitus. Pharmacotherapy. 2002;22:841-852.
20. Koller EA, Cross JT, Doraiswamy PM, Schneider BS. Risperidone-associated diabetes mellitus: a pharmacovigilance study. Pharmacotherapy. 2003;23:735-744.
21. Henderson DC. Clinical experience with insulin resistance, diabetic ketoacidosis, and type 2 diabetes mellitus in patients treated with atypical antipsychotic agents. J Clin Psychiatry. 2001;62(suppl 27):10-14; discussion 40-41.
22. Ryan MC, Collins P, Thakore JH. Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia. Am J Psychiatry. 2003;160:284-289.
23. Valdes CT, Elkind-Hirsch KE. Intravenous glucose tolerance test-derived insulin sensitivity changes during the menstrual cycle. J Clin Endocrinol Metab. 1991;72:642-646.
24. Spitzer RL, Williams JB, Gibbon M, First MB. The Structured Clinical Interview for DSM-III-R(SCID), I: history, rationale, and description. Arch Gen Psychiatry. 1992;49:624-629.
25. 1983 Metropolitan height and weight tables. Stat Bull Metropol Life Insur Co. 1983;64:3-9.
26. Durnin JV, Womersley J. Body fat assessed from total body density and its estimation from skinfold thickness: measurements on 481 men and women aged from 16 to 72 years. Br J Nutr. 1974;32:77-97.
27. Lange TG, Roche AF, Martorell R. Anthropometric Standardization Reference Manual. Champaign, III: Human Kinetics Books; 1988.
28. Schakel SF, Sievert YA, Buzzard IM. Sources of data for developing and maintaining a nutrient database. J Am Diet Assoc. 1988;88:1268-1271.
29. Lukaski HC, Bolonchuk WW, Hall CB, Siders WA. Validation of tetrapolar bioelectrical impedance method to assess human body composition. J Appl Physiol. 1986;60:1327-1332.
30. Kushner RF. Bioelectrical impedance analysis: a review of principles and applications. J Am Coll Nutr. 1992;11:199-209.
31. Ritz RCJ. Indirect Calorimetry: Monitoring in Respiratory Care. St Louis, Mo: Mosby-Yearbook, Inc; 1993.
32. Pereira MA, FitzerGerald SJ, Gregg EW, Joswiak ML, Ryan WJ, Suminski RR, Utter AC, Zmuda JM. A collection of physical activity questionnaires for health-related research. Med Sci Sports Exerc. 1997;29(suppl 6):S1-S205.
33. Bergman RN, Phillips LS, Cobelli C. Physiologic evaluation of factors controlling glucose tolerance in man: measurement of insulin sensitivity and beta-cell glucose sensitivity from the response to intravenous glucose. J Clin Invest. 1981;68:1456-1467.
34. Bergman RN. Lilly lecture 1989: toward physiological understanding of glucose tolerance: minimal-model approach. Diabetes. 1989;38:1512-1527.
35. Bergman RN, Watanabe R, Rebrin K, Ader M, Steil G. Toward an integrated phenotype in pre-NIDDM. Diabet Med. 1996;13:S67-S77.
36. McNamara J, Schaefer E. Automated enzymatic standardized lipid analyses for plasma lipoprotein fractions. Clin Chim Acta. 1987;166:1-8.
37. Warnick G, Benderson J, Albers J. Dextran sulfate-Mg2+ precipitation procedure for quantitation of high-density-lipoprotein cholesterol. Clin Chem. 1982;28:1379-1388.
38. Friedewald W, Levy R, Fredrickson D. Estimation of the concentration of low density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499-502.
39. Bergman RN, Prager R, Volund A, Olefsky JM. Equivalence of the insulin sensitivity index in man derived by the minimal model method and the euglycemic glucose clamp. J Clin Invest. 1987;79:790-800.
40. Kahn SE, Prigeon RL, McCulloch DK, Boyko EJ, Bergman RN, Schwartz MW, Neifing JL, Ward WK, Beard JC, Palmer JP. Quantification of the relationship between insulin sensitivity and beta-cell function in human subjects: evidence for a hyperbolic function. Diabetes. 1993;42:1663-1672.
41. Perez-Martin A, Raynaud E, Hentgen C, Bringer J, Mercier J, Brun JF. Simplified measurement of insulin sensitivity with the minimal model procedure in type 2 diabetic patients without measurement of insulinemia. Horm Metab Res. 2002;34:102-106.
42. Hermans MP, Levy JC, Morris RJ, Turner RC. Comparison of insulin sensitivity tests across a range of glucose tolerance from normal to diabetes. Diabetologia. 1999;42:678-687.
43. Haffner SM, Howard G, Mayer E, Bergman RN, Savage PJ, Rewers M, Mykkanen L, Karter AJ, Hamman R, Saad MF. Insulin sensitivity and acute insulin response in African-Americans, non-Hispanic whites, and Hispanics with NIDDM: the Insulin Resistance Atherosclerosis Study. Diabetes. 1997;46:63-69.
44. Watanabe RM, Azen CG, Roy S, Perlman JA, Bergman RN. Defects in carbohydrate metabolism in oral contraceptive users without apparent metabolic risk factors. J Clin Endocrinol Metab. 1994;79:1277-1283.
45. Haffner SM, O'Agostino R Jr, Festa A, Bergman RN, Mykkanen L, Karter A, Saad MF, Wagenknecht LE. Low insulin sensitivity (S(i) = 0) in diabetic and nondiabetic subjects in the Insulin Resistance Atherosclerosis Study: is it associated with components of the metabolic syndrome and nontraditional risk factors? Diabetes Care. 2003;26:2796-2803.
46. Sowell MO, Mukhopadhyay N, Cavazzoni P, Shankar S, Steinberg HO, Breier A, Beasley CM Jr, Dananberg J. Hyperglycemic clamp assessment of insulin secretory responses in normal subjects treated with olanzapine, risperidone, or placebo. J Clin Endocrinol Metab. 2002;87:2918-2923.
47. Best J, Kahn S, Ader M, Watanabe R, Ni T, Bergman R. Role of glucose effectiveness in the determination of glucose tolerance. Diabetes Care. 1996;19:1018-1030.
48. Dwyer DS, Pinkofsky HR, Lin Y, Bradley RJ. Antipsychotic drugs affect glucose uptake and the expression of glucose transporters in PC 12 cells. Prog Neuropsychopharmacol Biol Psychiatry. 1999;23:69-80.
49. Ader M, Catalano K, Ionut V, Kim S, Huecking K, Richey J, Bergman RN. Differential metabolic effects between atypical antipsychotics in normal dogs. Poster presented at: the 63rd Scientific Sessions of the American Diabetes Association Meeting; June 15, 2003; New Orleans, La.
50. Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC, Weiden PJ. Antipsychotic induced weight gain: a comprehensive research synthesis. Am J Psychiatry. 1999;156:1686-1696.
51. Macor C, Ruggeri A, Mazzonetto P, Federspil G, Cobelli C, Vettor R. Visceral adipose tissue impairs insulin secretion and insulin sensitivity but not energy expenditure in obesity. Metabolism. 1997;46:123-129.
52. Pi-Sunyer FX. The medical risks of obesity. Obes Surg. 2002;12(suppl 1):6S-11S.
53. Pi-Sunyer F. Medical hazards of obesity. Ann Intern Med. 1993;119:655-660.
54. Goodpaster BH, Krishnaswami S, Resnick H, Kelley DE, Haggerty C, Harris TB, Schwartz AV, Kritchevsky S, Newman AB. Association between regional adipose tissue distribution and both type 2 diabetes and impaired glucose tolerance in elderly men and women. Diabetes Care. 2003;26:372-379.
55. Hagg S, Soderberg S, Ahren B, Olsson T, Mjorndal T. Leptin concentrations are increased in subjects treated with clozapine or conventional antipsychotics. J Clin Psychiatry. 2001;62:843-848.
56. Herran A, Garcia-Unzueta MT, Amado JA, de La Maza MT, Alvarez C, Vazquez-Barquero JL. Effects of long-term treatment with antipsychotics on serum leptin levels. Br J Psychiatry. 2001;179:59-62.
57. Mukherjee S, Decina P, Bocola V, Saracini F, Scapicchio PL. Diabetes mellitus in schizophrenic patients. Compr Psychiatry. 1996;37:68-73.
58. Christie JE, Whalley LJ, Dick H, Blackwood DH, Blackburn IM, Fink G. Raised plasma cortisol concentrations a feature of drug-free psychotics and not specific for depression. Br J Psychiatry. 1986;148:58-65.
59. Whalley LJ, Christie JE, Blackwood DH, Bennie J, Dick H, Blackburn IM, Fink G. Disturbed endocrine function in the psychoses, I: disordered homeostasis or disease process? Br J Psychiatry. 1989;155:455-461.
60. Wik G. Effects of neuroleptic treatment on cortisol and 3-methoxy-4-hydroxyphenylethyl glycol levels in blood. J Endocrinol. 1995;144:425-429.
61. Henderson DC. Diabetes mellitus and other metabolic disturbances induced by atypical antipsychotic agents. Curr Diab Rep. 2002;2:135-140.
62. Consensus development conference on antipsychotic drugs and obesity and diabetes. J Clin Psychiatry. 2004;65:267-272.
63. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106:3143-3421.
64. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care. 2004;27:596-601.